27694930|t|Low Concentration of Sodium Butyrate from Ultrabraid + NaBu suture, Promotes Angiogenesis and Tissue Remodelling in Tendon - bones Injury
27694930|a|Sodium butyrate (NaBu), a form of short-chain fatty acid (SCFA), acts classically as a potent anti-angiogenic agent in tumour angiogenesis models, some authors demonstrated that low concentrations of NaBu may contribute to healing of tendon - bone injury in part at least through promotion of tissue remodelling. Here, we investigated the effects of low -range concentrations of NaBu using in vitro and in vivo assays using angiogenesis as the primary outcome measure and the mechanisms through which it acts. We demonstrated that NaBu, alone or perfused from the UltraBraid + NaBu suture was pro-angiogenic at very low -range doses promoting migration, tube formation and cell invasion in bovine aortic endothelial cells (BAECs). Furthermore, cell exposure to low NaBu concentrations increased expression of proteins involved in angiogenic cell signalling, including p-PKCβ1, p-FAK, p-ERK1 / 2, p-NFκβ, p-PLCγ1 and p-VEGFR2. In addition, inhibitors of both VEGFR2 and PKCβ1 blocked the angiogenic response. In in vivo assays, low concentrations of NaBu induced neovascularization in sponge implants in mice, evidenced by increased numbers of vessels and haemoglobin content in these implants. The findings in this study indicate that low concentrations of NaBu could be an important compound to stimulate angiogenesis at a site where vasculature is deficient and healing is compromised.
27694930	0	3	Low	T080	C0205251
27694930	4	17	Concentration	T081	C1446561
27694930	21	36	Sodium Butyrate	T109,T121	C0142812
27694930	42	52	Ultrabraid	T074	C0038969
27694930	55	59	NaBu	T109,T121	C0142812
27694930	60	66	suture	T074	C0038969
27694930	68	76	Promotes	T052	C0033414
27694930	77	89	Angiogenesis	T042	C0302600
27694930	94	112	Tissue Remodelling	T038	C1820201
27694930	116	122	Tendon	T023	C0039508
27694930	125	137	bones Injury	T037	C0561852
27694930	138	153	Sodium butyrate	T109,T121	C0142812
27694930	155	159	NaBu	T109,T121	C0142812
27694930	172	194	short-chain fatty acid	T109,T123	C0015691
27694930	196	200	SCFA	T109,T123	C0015691
27694930	232	253	anti-angiogenic agent	T121,T123	C0596087
27694930	257	263	tumour	T191	C0027651
27694930	264	276	angiogenesis	T042	C0302600
27694930	277	283	models	T050	C0684309
27694930	316	319	low	T080	C0205251
27694930	320	334	concentrations	T081	C1446561
27694930	338	342	NaBu	T109,T121	C0142812
27694930	361	368	healing	T040	C0043240
27694930	372	378	tendon	T023	C0039508
27694930	381	392	bone injury	T037	C0561852
27694930	410	417	through	T169	C0332273
27694930	418	427	promotion	T052	C0033414
27694930	431	449	tissue remodelling	T038	C1820201
27694930	477	487	effects of	T080	C1704420
27694930	488	491	low	T080	C0205251
27694930	499	513	concentrations	T081	C1446561
27694930	517	521	NaBu	T109,T121	C0142812
27694930	528	536	in vitro	T062	C1515653
27694930	541	548	in vivo	T082	C1515655
27694930	549	555	assays	T059	C0005507
27694930	562	574	angiogenesis	T042	C0302600
27694930	582	589	primary	T080	C0205225
27694930	590	605	outcome measure	T081	C0086749
27694930	614	624	mechanisms	T169	C0441712
27694930	625	632	through	T169	C0332273
27694930	669	673	NaBu	T109,T121	C0142812
27694930	702	712	UltraBraid	T074	C0038969
27694930	715	719	NaBu	T109,T121	C0142812
27694930	720	726	suture	T074	C0038969
27694930	731	745	pro-angiogenic	T042	C0302600
27694930	754	757	low	T080	C0205251
27694930	765	770	doses	T081	C0178602
27694930	771	780	promoting	T052	C0033414
27694930	781	790	migration	T043	C1622501
27694930	792	806	tube formation	T042	C2752214
27694930	811	824	cell invasion	T046	C2699153
27694930	828	834	bovine	T015	C3667982
27694930	835	841	aortic	T023	C0003483
27694930	842	859	endothelial cells	T025	C0225336
27694930	861	866	BAECs	T025	C0225336
27694930	882	886	cell	T025	C0007634
27694930	887	898	exposure to	T080	C0332157
27694930	899	902	low	T080	C0205251
27694930	903	907	NaBu	T109,T121	C0142812
27694930	908	922	concentrations	T081	C1446561
27694930	923	932	increased	T081	C0205217
27694930	933	955	expression of proteins	T045	C1171362
27694930	968	978	angiogenic	T042	C0302600
27694930	979	994	cell signalling	T043	C0037083
27694930	1006	1013	p-PKCβ1	T116,T126	C0257292
27694930	1015	1020	p-FAK	T116,T126	C0059239
27694930	1022	1028	p-ERK1	T116,T126	C0082529
27694930	1031	1032	2	T116,T126	C0170168
27694930	1034	1040	p-NFκβ	T116,T129	C0079904
27694930	1042	1049	p-PLCγ1	T116,T126	C0753837
27694930	1054	1062	p-VEGFR2	T116,T192	C0378796
27694930	1077	1087	inhibitors	T120	C0243077
27694930	1096	1102	VEGFR2	T116,T192	C0378796
27694930	1107	1112	PKCβ1	T116,T126	C0257292
27694930	1113	1120	blocked	T169	C0332206
27694930	1125	1135	angiogenic	T042	C0302600
27694930	1136	1144	response	T032	C0871261
27694930	1149	1156	in vivo	T082	C1515655
27694930	1157	1163	assays	T059	C0005507
27694930	1165	1168	low	T080	C0205251
27694930	1169	1183	concentrations	T081	C1446561
27694930	1187	1191	NaBu	T109,T121	C0142812
27694930	1192	1199	induced	T169	C0205263
27694930	1200	1218	neovascularization	T046	C0027686
27694930	1222	1237	sponge implants	T074	C0021102
27694930	1241	1245	mice	T015	C0026809
27694930	1260	1269	increased	T081	C0205217
27694930	1281	1288	vessels	T023	C0005847
27694930	1293	1304	haemoglobin	T116,T123	C0019046
27694930	1305	1312	content	T081	C1264655
27694930	1322	1330	implants	T074	C0021102
27694930	1373	1376	low	T080	C0205251
27694930	1377	1391	concentrations	T081	C1446561
27694930	1395	1399	NaBu	T109,T121	C0142812
27694930	1444	1456	angiogenesis	T042	C0302600
27694930	1462	1466	site	T029	C1515974
27694930	1473	1484	vasculature	T017	C3714653
27694930	1488	1497	deficient	T169	C0011155
27694930	1502	1509	healing	T040	C0043240
27694930	1513	1524	compromised	T033	C2945640